Leonardo Tomei
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Leonardo Tomei has a total of 114 co-authors. Here are the top co-authors by number of shared publications:
- Francesca Mori
Allergy Unit Meyer Children's Hospital IRCCS Florence Italy
28 shared publications - Simona Barni
Allergy Unit Meyer Children's Hospital IRCCS Florence Italy
26 shared publications - Giulia Liccioli
Allergy Unit Meyer Children's Hospital IRCCS Florence Italy
25 shared publications - Mattia Giovannini
Allergy Unit Meyer Children's Hospital IRCCS Florence Italy
25 shared publications - Lucrezia Sarti
Allergy Unit Meyer Children's Hospital IRCCS Florence Italy
24 shared publications - Benedetta Pessina
Allergy Unit Meyer Children's Hospital IRCCS Florence Italy
18 shared publications
Latest Publications
- 3 November 2026
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 37 (11)
Visual bias in the clinical history of pediatric cutaneous drug hypersensitivity reactions
Background: De‐labeling suspected adverse drug hypersensitivity reactions (DHRs) is a critical goal in clinical practice, as misdiagnosed allergies lead to unnecessary medicalization and unwarranted restrictions on available medications. In children, high‐risk factors for DHRs, such as immediate urticaria, often overlap with common viral rashes, complicating risk stratification. This challenge is compounded by caregiver‐reported histories, which can distort symptom timing and severity. This cross‐sectional comparative questionnaire study with a comparison group evaluated how caregivers and pediatric patients visually recognize common drug‐related skin eruptions and whether non‐clinical variables may affect recognition accuracy. Methods: Patients and caregivers referred to the Allergy Units of two tertiary care hospitals for suspected DHRs were included. Questionnaires were offered to caregivers and patients aged 7–17. Participants were divided into two groups: patients with suspected DHRs and subjects without a history of DHRs. Enrolled subjects were asked to recognize pictures of maculopapular, micropapular, and urticaria via a multiple‐choice questionnaire. Results: Data from 405 participants were collected between September 2023 and August 2024. Statistical analysis showed that higher caregiver education and a positive personal history of DHRs and/or urticaria significantly improved recognition accuracy. Nevertheless, nearly half of participants with suspected DHR history misidentified urticaria as micropapular rash. Rash recognition skills did not differ significantly between healthcare and non‐healthcare caregivers. Conclusion: These findings highlight the need for systematic approaches beyond descriptive histories. Integrating non‐clinical factors into diagnostic frameworks could enhance risk stratification and support safer and more effective allergy workup for de‐labeling suspected DHRs in pediatric patients. image
- 3 November 2026
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 37 (11)
Visual bias in the clinical history of pediatric cutaneous drug hypersensitivity reactions
Background: De‐labeling suspected adverse drug hypersensitivity reactions (DHRs) is a critical goal in clinical practice, as misdiagnosed allergies lead to unnecessary medicalization and unwarranted restrictions on available medications. In children, high‐risk factors for DHRs, such as immediate urticaria, often overlap with common viral rashes, complicating risk stratification. This challenge is compounded by caregiver‐reported histories, which can distort symptom timing and severity. This cross‐sectional comparative questionnaire study with a comparison group evaluated how caregivers and pediatric patients visually recognize common drug‐related skin eruptions and whether non‐clinical variables may affect recognition accuracy. Methods: Patients and caregivers referred to the Allergy Units of two tertiary care hospitals for suspected DHRs were included. Questionnaires were offered to caregivers and patients aged 7–17. Participants were divided into two groups: patients with suspected DHRs and subjects without a history of DHRs. Enrolled subjects were asked to recognize pictures of maculopapular, micropapular, and urticaria via a multiple‐choice questionnaire. Results: Data from 405 participants were collected between September 2023 and August 2024. Statistical analysis showed that higher caregiver education and a positive personal history of DHRs and/or urticaria significantly improved recognition accuracy. Nevertheless, nearly half of participants with suspected DHR history misidentified urticaria as micropapular rash. Rash recognition skills did not differ significantly between healthcare and non‐healthcare caregivers. Conclusion: These findings highlight the need for systematic approaches beyond descriptive histories. Integrating non‐clinical factors into diagnostic frameworks could enhance risk stratification and support safer and more effective allergy workup for de‐labeling suspected DHRs in pediatric patients. image
- 17 August 2026
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 37 (8) , e70430
Editorial comment on: Direct single dose mass delabeling of antibiotic allergy in pediatrics
- 17 August 2026
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 37 (8) , e70430
Editorial comment on: Direct single dose mass delabeling of antibiotic allergy in pediatrics
- Open Access
- 10 June 2026
- Published by Wiley in Contact Dermatitis
- Vol. 95 (4) , 349-357
Patch Testing in Paediatric Drug Hypersensitivity Reactions: Current Evidence and Clinical Implications
Drug hypersensitivity reactions (DHRs) are common in children and are diagnostically challenging, with cutaneous manifestations being the most common presentation. Patch testing (PT) is a well‐established tool for investigating delayed T‐cell‐mediated reactions and is widely used in patients with contact dermatitis. However, its role in paediatric DHRs remains unclear. Available data indicate that PT is safe and particularly useful when drug provocation testing is contraindicated, such as in patients with severe cutaneous adverse reactions. However, diagnostic yield varies considerably among drug classes and clinical phenotypes. Sensitivity is generally low for beta‐lactam and most non–beta‐lactam antibiotics, which limits their standalone value in common exanthematous reactions. Higher positivity rates have been reported for antiepileptic drugs, and PT may help identify the culprit drug and assess its cross‐reactivity. However, evidence supporting the use of nonsteroidal anti‐inflammatory drugs and paracetamol remains scarce. Methodological heterogeneity and limited paediatric‐specific data further constrain this interpretation. Overall, PT should be considered as a complementary diagnostic tool integrated with clinical history and other tests, highlighting the need for standardized protocols and prospective paediatric studies.
- 10 June 2026
- Published by Wiley in Contact Dermatitis
- Vol. 95 (4) , 349-357
Open AccessPatch Testing in Paediatric Drug Hypersensitivity Reactions: Current Evidence and Clinical Implications
Drug hypersensitivity reactions (DHRs) are common in children and are diagnostically challenging, with cutaneous manifestations being the most common presentation. Patch testing (PT) is a well‐established tool for investigating delayed T‐cell‐mediated reactions and is widely used in patients with contact dermatitis. However, its role in paediatric DHRs remains unclear. Available data indicate that PT is safe and particularly useful when drug provocation testing is contraindicated, such as in patients with severe cutaneous adverse reactions. However, diagnostic yield varies considerably among drug classes and clinical phenotypes. Sensitivity is generally low for beta‐lactam and most non–beta‐lactam antibiotics, which limits their standalone value in common exanthematous reactions. Higher positivity rates have been reported for antiepileptic drugs, and PT may help identify the culprit drug and assess its cross‐reactivity. However, evidence supporting the use of nonsteroidal anti‐inflammatory drugs and paracetamol remains scarce. Methodological heterogeneity and limited paediatric‐specific data further constrain this interpretation. Overall, PT should be considered as a complementary diagnostic tool integrated with clinical history and other tests, highlighting the need for standardized protocols and prospective paediatric studies.
- Open Access
- 10 June 2026
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 37 (6) , e70394
Health inequities in pediatric anaphylaxis: A policy framework and call to action for equitable care from SIAIP allergy prevention commission
Pediatric anaphylaxis is a rapidly evolving and potentially fatal allergic reaction whose incidence is increasing worldwide, particularly among young children. Despite international guidelines identifying intramuscular epinephrine as the first‐line, life‐saving treatment, significant health inequities persist in the prevention, recognition, and management of pediatric anaphylaxis. This manuscript, developed by the Primary and Secondary Prevention of Allergic Diseases Committee of the Italian Society of Pediatric Allergy and Immunology (SIAIP), moves beyond a traditional narrative review by integrating current evidence with a structured policy‐oriented framework. Evidence highlights pronounced socioeconomic, racial, cultural, biological, and geographic inequities influencing disease burden, access to specialist care, prescription and availability of epinephrine autoinjectors (EAIs), training of caregivers and healthcare professionals, and timely epinephrine use in emergency settings. Building on this evidence, we propose a SIAIP‐driven call to action and outline a preliminary national policy framework aimed at reducing inequities through coordinated interventions. Key priorities include equitable access to EAIs, standardized and repeated practical training, school‐based preparedness programs, public awareness initiatives, integration of psychological support, and the development of national monitoring systems. By translating evidence into actionable strategies, this work provides a national perspective that complements existing international recommendations and offers a model for other countries seeking to address disparities in pediatric anaphylaxis care.
- 10 June 2026
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 37 (6) , e70394
Open AccessHealth inequities in pediatric anaphylaxis: A policy framework and call to action for equitable care from SIAIP allergy prevention commission
Pediatric anaphylaxis is a rapidly evolving and potentially fatal allergic reaction whose incidence is increasing worldwide, particularly among young children. Despite international guidelines identifying intramuscular epinephrine as the first‐line, life‐saving treatment, significant health inequities persist in the prevention, recognition, and management of pediatric anaphylaxis. This manuscript, developed by the Primary and Secondary Prevention of Allergic Diseases Committee of the Italian Society of Pediatric Allergy and Immunology (SIAIP), moves beyond a traditional narrative review by integrating current evidence with a structured policy‐oriented framework. Evidence highlights pronounced socioeconomic, racial, cultural, biological, and geographic inequities influencing disease burden, access to specialist care, prescription and availability of epinephrine autoinjectors (EAIs), training of caregivers and healthcare professionals, and timely epinephrine use in emergency settings. Building on this evidence, we propose a SIAIP‐driven call to action and outline a preliminary national policy framework aimed at reducing inequities through coordinated interventions. Key priorities include equitable access to EAIs, standardized and repeated practical training, school‐based preparedness programs, public awareness initiatives, integration of psychological support, and the development of national monitoring systems. By translating evidence into actionable strategies, this work provides a national perspective that complements existing international recommendations and offers a model for other countries seeking to address disparities in pediatric anaphylaxis care.
- Open Access
IgE-Mediated Legume Allergy in Children: Insights from a Single-Center Experience in Italy
Background/Objectives: Legume allergy is increasingly recognized as plant-based diets expand and legume proteins are widely used in processed foods. We aimed to characterize the clinical features, sensitization profiles, and management outcomes of IgE-mediated legume allergy in Italian children. Methods: This retrospective single-center study (January 2022–January 2024) included children (p = 0.013) and liver transplantation (21% vs. 2%; p = 0.047). Peanut co-allergy occurred in 25.5%. Among 34 oral food challenges (OFCs), 23.5% were positive, including one case of pea-induced anaphylaxis. Of 16 oral immunotherapy (OIT) protocols initiated, 31.3% reached the full target maintenance dose, 37.5% remained on a lower, partial maintenance dose, and 31.3% were discontinued due to oral allergy syndrome (OAS). Conclusions: Pediatric legume allergy is characterized by early onset, frequent multi-legume involvement, and common co-allergies. In this cohort, pea allergy was associated with the highest proportion of severe reactions. Species-specific differences in severity, patterns of multi-legume involvement, and OIT outcomes should be interpreted cautiously given the limited sample size, while highlighting the need for tailored management and improved risk assessment across legume species.
Open AccessIgE-Mediated Legume Allergy in Children: Insights from a Single-Center Experience in Italy
Background/Objectives: Legume allergy is increasingly recognized as plant-based diets expand and legume proteins are widely used in processed foods. We aimed to characterize the clinical features, sensitization profiles, and management outcomes of IgE-mediated legume allergy in Italian children. Methods: This retrospective single-center study (January 2022–January 2024) included children (p = 0.013) and liver transplantation (21% vs. 2%; p = 0.047). Peanut co-allergy occurred in 25.5%. Among 34 oral food challenges (OFCs), 23.5% were positive, including one case of pea-induced anaphylaxis. Of 16 oral immunotherapy (OIT) protocols initiated, 31.3% reached the full target maintenance dose, 37.5% remained on a lower, partial maintenance dose, and 31.3% were discontinued due to oral allergy syndrome (OAS). Conclusions: Pediatric legume allergy is characterized by early onset, frequent multi-legume involvement, and common co-allergies. In this cohort, pea allergy was associated with the highest proportion of severe reactions. Species-specific differences in severity, patterns of multi-legume involvement, and OIT outcomes should be interpreted cautiously given the limited sample size, while highlighting the need for tailored management and improved risk assessment across legume species.
- Open Access
Peanut Oral Immunotherapy in Children: An Italian Single-Center Retrospective Cohort Study
Introduction: Peanut oral immunotherapy (P-OIT) is an emerging treatment strategy for peanut allergy (PA). Although a standardized pharmaceutical product, Peanut (Arachis hypogaea) Allergen Powder-dnfp, has been approved in several countries, it is not universally available. In such contexts, real-world protocols using readily utilizable peanut products may represent an alternative approach. This study aimed to describe the feasibility, safety, and clinical outcomes of P-OIT using toasted peanuts in a real-world effort in a pediatric population. Methods: This single-center retrospective cohort study enrolled children who initiated P-OIT at our tertiary pediatric hospital Allergy Unit between April 2015 and December 2024. Demographic and clinical features, allergy test results, and information about P-OIT were recorded. Desensitization was defined as tolerance of 630 mg of peanut protein (PP). Results: Sixty patients (51.7% male; median age 8.2 years) were included. 22/60 (36.7%) achieved desensitization within a median time of 22.7 months. 21/60 (35%) were still undergoing P-OIT at a median tolerated dose of 100 mg of PP, and 17/60 (28.3%) discontinued treatment, most commonly due to loss to follow-up (44%). At least one adverse reaction occurred in 43/60 (71.7%) patients, predominantly mild and self-limiting (68.3% resolved spontaneously, 39.5% occurred at home). However, 11/60 (18.3%) showed anaphylaxis, and 3/60 (5%) received adrenaline. A reduction in Ara h 2 serum-specific IgE levels compared to the baseline was observed in patients completing escalation (p = 0.03). Conclusions: In this real-world single-center cohort, P-OIT using toasted peanuts was feasible in a subset of patients and was associated predominantly with mild adverse reactions, although systemic reactions were also recorded. Treatment discontinuation and adherence remain relevant challenges. These findings highlight the need for prospective, controlled studies to better define the role, safety profile, and patient selection criteria for food-based P-OIT protocols in settings where standardized products are not available.
Open AccessPeanut Oral Immunotherapy in Children: An Italian Single-Center Retrospective Cohort Study
Introduction: Peanut oral immunotherapy (P-OIT) is an emerging treatment strategy for peanut allergy (PA). Although a standardized pharmaceutical product, Peanut (Arachis hypogaea) Allergen Powder-dnfp, has been approved in several countries, it is not universally available. In such contexts, real-world protocols using readily utilizable peanut products may represent an alternative approach. This study aimed to describe the feasibility, safety, and clinical outcomes of P-OIT using toasted peanuts in a real-world effort in a pediatric population. Methods: This single-center retrospective cohort study enrolled children who initiated P-OIT at our tertiary pediatric hospital Allergy Unit between April 2015 and December 2024. Demographic and clinical features, allergy test results, and information about P-OIT were recorded. Desensitization was defined as tolerance of 630 mg of peanut protein (PP). Results: Sixty patients (51.7% male; median age 8.2 years) were included. 22/60 (36.7%) achieved desensitization within a median time of 22.7 months. 21/60 (35%) were still undergoing P-OIT at a median tolerated dose of 100 mg of PP, and 17/60 (28.3%) discontinued treatment, most commonly due to loss to follow-up (44%). At least one adverse reaction occurred in 43/60 (71.7%) patients, predominantly mild and self-limiting (68.3% resolved spontaneously, 39.5% occurred at home). However, 11/60 (18.3%) showed anaphylaxis, and 3/60 (5%) received adrenaline. A reduction in Ara h 2 serum-specific IgE levels compared to the baseline was observed in patients completing escalation (p = 0.03). Conclusions: In this real-world single-center cohort, P-OIT using toasted peanuts was feasible in a subset of patients and was associated predominantly with mild adverse reactions, although systemic reactions were also recorded. Treatment discontinuation and adherence remain relevant challenges. These findings highlight the need for prospective, controlled studies to better define the role, safety profile, and patient selection criteria for food-based P-OIT protocols in settings where standardized products are not available.
- 22 March 2026
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 37 (3) , e70322
Increase of post–SARS‐CoV‐2 rashes mimicking penicillin allergy in children with Group A beta‐hemolytic Streptococcus infection: An emerging and challenging issue
Background: Group A beta‐hemolytic Streptococcus (GABHS) infections have surged globally in the post–SARS‐CoV‐2 era, coinciding with an increase in the number of children referred for suspected delayed hypersensitivity to penicillin administered during acute infection. GABHS‐related rashes may resemble non‐immediate drug reactions, complicating diagnosis, and contributing to inappropriate penicillin allergy diagnosis. Methods: Medical charts from patients followed at Allergy Unit of Meyer Children's Hospital IRCCS, Florence, Italy and Pediatric Department of “Vittore Buzzi” Children's Hospital, Milan, Italy, who underwent a penicillin drug provocation test (DPTs) between August 2015 and August 2025, were retrospectively reviewed. Only patients with documented, laboratory‐confirmed GABHS infections treated with penicillin were included. Results: Seventy patients treated with penicillin for concomitant GABHS infections that developed rash during therapy were included. The median time to rash insurgence was after 7 days of treatment (IQR = 4 days). Maculopapular rash was the most frequent (43/70, 61.4%) followed by urticarial rash in the remaining cases (27/70, 38.6%). No systemic reactions were reported. DPTs were negative in 63/70 (90%) patients, with only mild cutaneous reactions in the remaining cases, all manageable with antihistamines. All patients who experienced a positive DPT initially reported an urticarial rash as the reason for referral, whereas all patients with a history of maculopapular rash as the index reaction showed a negative DPT. Conclusion: GABHS may be associated with a rash that mimics delayed penicillin allergy, which is excluded by negative DPTs.
- 22 March 2026
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 37 (3) , e70322
Increase of post–SARS‐CoV‐2 rashes mimicking penicillin allergy in children with Group A beta‐hemolytic Streptococcus infection: An emerging and challenging issue
Background: Group A beta‐hemolytic Streptococcus (GABHS) infections have surged globally in the post–SARS‐CoV‐2 era, coinciding with an increase in the number of children referred for suspected delayed hypersensitivity to penicillin administered during acute infection. GABHS‐related rashes may resemble non‐immediate drug reactions, complicating diagnosis, and contributing to inappropriate penicillin allergy diagnosis. Methods: Medical charts from patients followed at Allergy Unit of Meyer Children's Hospital IRCCS, Florence, Italy and Pediatric Department of “Vittore Buzzi” Children's Hospital, Milan, Italy, who underwent a penicillin drug provocation test (DPTs) between August 2015 and August 2025, were retrospectively reviewed. Only patients with documented, laboratory‐confirmed GABHS infections treated with penicillin were included. Results: Seventy patients treated with penicillin for concomitant GABHS infections that developed rash during therapy were included. The median time to rash insurgence was after 7 days of treatment (IQR = 4 days). Maculopapular rash was the most frequent (43/70, 61.4%) followed by urticarial rash in the remaining cases (27/70, 38.6%). No systemic reactions were reported. DPTs were negative in 63/70 (90%) patients, with only mild cutaneous reactions in the remaining cases, all manageable with antihistamines. All patients who experienced a positive DPT initially reported an urticarial rash as the reason for referral, whereas all patients with a history of maculopapular rash as the index reaction showed a negative DPT. Conclusion: GABHS may be associated with a rash that mimics delayed penicillin allergy, which is excluded by negative DPTs.
- Open Access
- 23 February 2026
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 37 (2)
Hazelnut oral immunotherapy in children: An Italian single‐center retrospective cohort study
Introduction: Hazelnut oral immunotherapy (H‐OIT) is a promising treatment for hazelnut allergy (HA). The aim of this study was to assess the safety and efficacy of H‐OIT in a pediatric population, while describing its clinical and allergy characteristics. Methods: Children undergoing H‐OIT at our tertiary pediatric hospital Allergy Unit between April 2015 and December 2024 were enrolled. Demographic and clinical features, allergy test results and information on H‐OIT were recorded. Results: 124 patients (58.1% male; median age 8.5 years) were enrolled, 73 (58.9%) aged p < 0.001) and Cor a 14 IgE levels ( p = 0.004) were observed. A positive family history of atopy was associated with lower odds of completing H‐OIT (odds ratio 0.221, 95% confidence interval 0.055–0.895, p = 0.034). Conclusion: H‐OIT may be an effective treatment option for children with HA despite the high discontinuation rate. One quarter of patients remained on a lower, partial maintenance dose. Although the overall safety profile of H‐OIT seems acceptable, anaphylactic events represent a significant burden for families and must be carefully considered when weighing the risks and benefits of OIT.
- 23 February 2026
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 37 (2)
Open AccessHazelnut oral immunotherapy in children: An Italian single‐center retrospective cohort study
Introduction: Hazelnut oral immunotherapy (H‐OIT) is a promising treatment for hazelnut allergy (HA). The aim of this study was to assess the safety and efficacy of H‐OIT in a pediatric population, while describing its clinical and allergy characteristics. Methods: Children undergoing H‐OIT at our tertiary pediatric hospital Allergy Unit between April 2015 and December 2024 were enrolled. Demographic and clinical features, allergy test results and information on H‐OIT were recorded. Results: 124 patients (58.1% male; median age 8.5 years) were enrolled, 73 (58.9%) aged p < 0.001) and Cor a 14 IgE levels ( p = 0.004) were observed. A positive family history of atopy was associated with lower odds of completing H‐OIT (odds ratio 0.221, 95% confidence interval 0.055–0.895, p = 0.034). Conclusion: H‐OIT may be an effective treatment option for children with HA despite the high discontinuation rate. One quarter of patients remained on a lower, partial maintenance dose. Although the overall safety profile of H‐OIT seems acceptable, anaphylactic events represent a significant burden for families and must be carefully considered when weighing the risks and benefits of OIT.